JP2016518448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518448A5 JP2016518448A5 JP2016514017A JP2016514017A JP2016518448A5 JP 2016518448 A5 JP2016518448 A5 JP 2016518448A5 JP 2016514017 A JP2016514017 A JP 2016514017A JP 2016514017 A JP2016514017 A JP 2016514017A JP 2016518448 A5 JP2016518448 A5 JP 2016518448A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- membered saturated
- alkyl
- compound
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 11
- 229920006395 saturated elastomer Polymers 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 206010015150 Erythema Diseases 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 231100000321 erythema Toxicity 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims 2
- 208000001126 Keratosis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 206010053177 Epidermolysis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 102000000344 Sirtuin 1 Human genes 0.000 claims 1
- 108010041191 Sirtuin 1 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000004526 exfoliative dermatitis Diseases 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000001875 irritant dermatitis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822758P | 2013-05-13 | 2013-05-13 | |
| US61/822,758 | 2013-05-13 | ||
| PCT/US2014/037767 WO2014186313A1 (en) | 2013-05-13 | 2014-05-13 | Substituted bridged urea analogs as sirtuin modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518448A JP2016518448A (ja) | 2016-06-23 |
| JP2016518448A5 true JP2016518448A5 (https=) | 2017-06-29 |
| JP6376707B2 JP6376707B2 (ja) | 2018-08-22 |
Family
ID=53264426
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514017A Expired - Fee Related JP6376707B2 (ja) | 2013-05-13 | 2014-05-13 | サーチュイン調節剤としての置換架橋尿素類似体 |
| JP2017526877A Expired - Fee Related JP6833686B2 (ja) | 2013-05-13 | 2015-11-19 | サーチュイン調節剤としての置換架橋尿素類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526877A Expired - Fee Related JP6833686B2 (ja) | 2013-05-13 | 2015-11-19 | サーチュイン調節剤としての置換架橋尿素類似体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9765075B2 (https=) |
| EP (2) | EP2997029B1 (https=) |
| JP (2) | JP6376707B2 (https=) |
| KR (2) | KR20160006215A (https=) |
| CN (2) | CN105392788B (https=) |
| AU (3) | AU2014265671B2 (https=) |
| BR (2) | BR112015028613A2 (https=) |
| CA (2) | CA2912683A1 (https=) |
| ES (1) | ES2718550T3 (https=) |
| RU (2) | RU2015153061A (https=) |
| WO (1) | WO2014186313A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2982670B1 (en) * | 2013-04-04 | 2018-11-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN105392788B (zh) | 2013-05-13 | 2018-10-23 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的桥连脲类似物 |
| JP2016079173A (ja) * | 2014-10-15 | 2016-05-16 | 日本合成化学工業株式会社 | 新規ピリジン系化合物、それを用いたアニオン硬化性化合物用硬化剤、硬化性組成物及び硬化物 |
| JP6806679B2 (ja) * | 2014-11-19 | 2021-01-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | サーチュイン調節因子としての置換架橋尿素類似体 |
| WO2016095089A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| WO2016095088A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| CA3072103A1 (en) * | 2017-08-21 | 2019-02-28 | Microbiotix, Inc. | Metabolically stable n-acylaminooxadiazoles useful as antibacterial agents |
| JP7156207B2 (ja) * | 2019-08-07 | 2022-10-19 | 株式会社島津製作所 | 糖ペプチド解析装置 |
| CN112759593A (zh) | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
| CN112094362B (zh) * | 2020-09-29 | 2022-04-12 | 四川大学华西医院 | 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用 |
| CN112645805A (zh) * | 2020-12-23 | 2021-04-13 | 北京理工大学 | 一种由温勒伯酰胺制备均苯三甲醛的方法 |
| CN115518062B (zh) * | 2022-09-02 | 2024-03-22 | 成都大学 | Phellopterin在制备用于治疗STAT信号通路介导的相关疾病药物中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE4424484A1 (de) * | 1994-07-12 | 1996-01-18 | Bayer Ag | Azofarbstoffe, deren Herstellung und Verwendung |
| WO2006008119A1 (en) * | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ， インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
| WO2006094248A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Aryl-substituted cyclic sirtuin modulators |
| WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
| US20060229265A1 (en) | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| EP2099445B1 (en) * | 2006-09-04 | 2010-11-17 | University Court of The University of Dundee | P53 activating benzoyl urea and benzoyl thiourea compounds |
| BRPI0821676A2 (pt) * | 2007-12-21 | 2015-06-16 | Astrazeneca Ab | Composto, composição farmacêutica, e, processo para a preparação dos compostos. |
| EA021938B1 (ru) * | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
| US9326986B2 (en) | 2008-09-29 | 2016-05-03 | Glaxosmithkline Llc | Quinazolinone, quinolone and related analogs as sirtuin modulators |
| WO2010056549A1 (en) | 2008-10-29 | 2010-05-20 | Sirtris Pharmaceuticals, Inc. | Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
| EP2376502B1 (en) | 2008-12-19 | 2015-06-17 | GlaxoSmithKline LLC | Thiazolopyridine sirtuin modulating compounds |
| US9556201B2 (en) * | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| RU2014120180A (ru) * | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и аналоги в качестве модуляторов сиртуина |
| WO2016081692A2 (en) | 2014-11-19 | 2016-05-26 | Glaxosmithkline Llc | Substituted bridged urea analogs as sirtuin modulators |
| CN105392788B (zh) | 2013-05-13 | 2018-10-23 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的桥连脲类似物 |
-
2014
- 2014-05-13 CN CN201480040001.7A patent/CN105392788B/zh not_active Expired - Fee Related
- 2014-05-13 ES ES14798509T patent/ES2718550T3/es active Active
- 2014-05-13 RU RU2015153061A patent/RU2015153061A/ru unknown
- 2014-05-13 JP JP2016514017A patent/JP6376707B2/ja not_active Expired - Fee Related
- 2014-05-13 BR BR112015028613A patent/BR112015028613A2/pt not_active Application Discontinuation
- 2014-05-13 CA CA2912683A patent/CA2912683A1/en not_active Abandoned
- 2014-05-13 US US14/891,158 patent/US9765075B2/en not_active Expired - Fee Related
- 2014-05-13 EP EP14798509.7A patent/EP2997029B1/en active Active
- 2014-05-13 AU AU2014265671A patent/AU2014265671B2/en not_active Ceased
- 2014-05-13 KR KR1020157034916A patent/KR20160006215A/ko not_active Ceased
- 2014-05-13 WO PCT/US2014/037767 patent/WO2014186313A1/en not_active Ceased
- 2014-11-19 US US14/547,861 patent/US9834558B2/en not_active Expired - Fee Related
-
2015
- 2015-11-19 CN CN201580074601.XA patent/CN107207496A/zh active Pending
- 2015-11-19 RU RU2017120859A patent/RU2017120859A/ru unknown
- 2015-11-19 BR BR112017010592A patent/BR112017010592A2/pt not_active Application Discontinuation
- 2015-11-19 AU AU2015349912A patent/AU2015349912A1/en not_active Abandoned
- 2015-11-19 US US15/528,195 patent/US10590135B2/en active Active
- 2015-11-19 CA CA2975291A patent/CA2975291A1/en not_active Abandoned
- 2015-11-19 JP JP2017526877A patent/JP6833686B2/ja not_active Expired - Fee Related
- 2015-11-19 EP EP15861618.5A patent/EP3221312A4/en not_active Withdrawn
- 2015-11-19 KR KR1020177016322A patent/KR20170084274A/ko not_active Withdrawn
-
2017
- 2017-06-20 AU AU2017204176A patent/AU2017204176B2/en not_active Ceased
- 2017-08-04 US US15/669,301 patent/US20180044338A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518448A5 (https=) | ||
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| MX383051B (es) | Compuestos que inhiben eif4a y métodos relacionados a los mismos. | |
| CU20160097A7 (es) | Compuestos de imidazopirazina como inhibidores de syk | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| MX2014015501A (es) | Carboxamidas heterociclicas fungicidas. | |
| AR096238A1 (es) | Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo | |
| JP2016526024A5 (https=) | ||
| EA201690094A1 (ru) | Ингибиторы syk | |
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| MX375261B (es) | Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca. | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| BR112016007427A2 (pt) | compostos de pirazol-amida e usos dos mesmos | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| MX2015003594A (es) | Agente terapeutico o profilactico para sindrome de lisis tumoral. | |
| RU2020123900A (ru) | Новые соединения, ингибирующие mtor | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| RU2020123899A (ru) | Новые соединения, ингибирующие mtor | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| PE20131327A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen | |
| MX388141B (es) | EL USO DE DERIVADOS DE ÁCIDOS GRASOS POLINSATURADOS PARA REDUCIR apoC-III. | |
| AR091402A1 (es) | Profarmacos de acido fosforadimico |